TipRanks
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
US Market
AXSM
Axsome Therapeutics
RESEARCH TOOLSreports
Want to see AXSM full AI Analyst Report?

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

2,411 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Strong Buy
17Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$285.88
▲(39.13% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $285.88 with a high forecast of $380.00 and a low forecast of $247.00. The average price target represents a 39.13% change from the last price of $205.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"117":"$117","183":"$183","249":"$249","315":"$315","381":"$381"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":285.875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$285.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":247,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$247.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[117,183,249,315,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.07,197.29538461538462,212.52076923076922,227.74615384615385,242.97153846153844,258.1969230769231,273.4223076923077,288.6476923076923,303.87307692307695,319.09846153846155,334.32384615384615,349.5492307692308,364.7746153846154,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.07,190.055,198.04,206.025,214.01,221.995,229.98,237.965,245.95,253.935,261.92,269.905,277.89,{"y":285.875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.07,187.06461538461537,192.05923076923077,197.05384615384614,202.04846153846154,207.0430769230769,212.0376923076923,217.03230769230768,222.02692307692308,227.02153846153846,232.01615384615386,237.01076923076923,242.00538461538463,{"y":247,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.83,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.07,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$380.00Average Price Target$285.88Lowest Price Target$247.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on AXSM
Unknown Analyst
UBS
Not Ranked
UBS
$280→$256
Buy
24.59%
Upside
Reiterated
10/15/26
UBS Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Needham Analyst forecast on AXSM
Ami Fadia
Needham
Needham
$268
Buy
30.43%
Upside
Reiterated
10/15/26
Needham Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
RBC Capital Analyst forecast on AXSM
Leonid Timashev
RBC Capital
RBC Capital
$295
Buy
43.57%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (NASDAQ: STLN), Axsome Therapeutics (NASDAQ: AXSM) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
BMO Capital Analyst forecast on AXSM
Evan Seigerman
BMO Capital
BMO Capital
$310
Buy
50.87%
Upside
Reiterated
10/12/26
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Axsome Therapeutics (AXSM)
Bank of America Securities Analyst forecast on AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$276
Buy
34.32%
Upside
Reiterated
10/09/26
Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities
Oppenheimer Analyst forecast on AXSM
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$280
Buy
36.27%
Upside
Reiterated
10/06/26
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), AbbVie (ABBV)
Wells Fargo Analyst forecast on AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$256
Buy
24.59%
Upside
Assigned
10/01/26
Wells Fargo Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Deutsche Bank Analyst forecast on AXSM
David Hoang
Deutsche Bank
Deutsche Bank
$280→$267
Buy
29.94%
Upside
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), ClearPoint Neuro (NASDAQ: CLPT) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$247
Hold
20.21%
Upside
Reiterated
09/25/26
Axsome Therapeutics price target lowered to $247 from $251 at Morgan StanleyAxsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley
H.C. Wainwright Analyst forecast on AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$290
Buy
41.13%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Scholar Rock Holding (NASDAQ: SRRK) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Truist Financial Analyst forecast on AXSM
Srikripa Devarakonda
Truist Financial
Truist Financial
$200→$285
Buy
38.70%
Upside
Initiated
09/23/26
Axsome Therapeutics (AXSM) Has a New Rating from Truist Financial
Piper Sandler Analyst forecast on AXSM
David Amsellem
Piper Sandler
Piper Sandler
$258
Buy
25.56%
Upside
Reiterated
09/18/26
Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Mizuho Securities Analyst forecast on AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$316
Buy
53.79%
Upside
Reiterated
09/11/26
Axsome rises as Mizuho highlights 'big month-over-month jump' for AuvelityAxsome rises as Mizuho highlights 'big month-over-month jump' for Auvelity
Jefferies Analyst forecast on AXSM
Andrew Tsai
Jefferies
Jefferies
$380
Buy
84.93%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
William Blair Analyst forecast on AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on AXSM
Unknown Analyst
UBS
Not Ranked
UBS
$280→$256
Buy
24.59%
Upside
Reiterated
10/15/26
UBS Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Needham Analyst forecast on AXSM
Ami Fadia
Needham
Needham
$268
Buy
30.43%
Upside
Reiterated
10/15/26
Needham Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
RBC Capital Analyst forecast on AXSM
Leonid Timashev
RBC Capital
RBC Capital
$295
Buy
43.57%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (NASDAQ: STLN), Axsome Therapeutics (NASDAQ: AXSM) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
BMO Capital Analyst forecast on AXSM
Evan Seigerman
BMO Capital
BMO Capital
$310
Buy
50.87%
Upside
Reiterated
10/12/26
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Axsome Therapeutics (AXSM)
Bank of America Securities Analyst forecast on AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$276
Buy
34.32%
Upside
Reiterated
10/09/26
Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities
Oppenheimer Analyst forecast on AXSM
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$280
Buy
36.27%
Upside
Reiterated
10/06/26
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), AbbVie (ABBV)
Wells Fargo Analyst forecast on AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$256
Buy
24.59%
Upside
Assigned
10/01/26
Wells Fargo Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Deutsche Bank Analyst forecast on AXSM
David Hoang
Deutsche Bank
Deutsche Bank
$280→$267
Buy
29.94%
Upside
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), ClearPoint Neuro (NASDAQ: CLPT) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$247
Hold
20.21%
Upside
Reiterated
09/25/26
Axsome Therapeutics price target lowered to $247 from $251 at Morgan StanleyAxsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley
H.C. Wainwright Analyst forecast on AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$290
Buy
41.13%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Scholar Rock Holding (NASDAQ: SRRK) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Truist Financial Analyst forecast on AXSM
Srikripa Devarakonda
Truist Financial
Truist Financial
$200→$285
Buy
38.70%
Upside
Initiated
09/23/26
Axsome Therapeutics (AXSM) Has a New Rating from Truist Financial
Piper Sandler Analyst forecast on AXSM
David Amsellem
Piper Sandler
Piper Sandler
$258
Buy
25.56%
Upside
Reiterated
09/18/26
Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Mizuho Securities Analyst forecast on AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$316
Buy
53.79%
Upside
Reiterated
09/11/26
Axsome rises as Mizuho highlights 'big month-over-month jump' for AuvelityAxsome rises as Mizuho highlights 'big month-over-month jump' for Auvelity
Jefferies Analyst forecast on AXSM
Andrew Tsai
Jefferies
Jefferies
$380
Buy
84.93%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
William Blair Analyst forecast on AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
SIBNSI-Bone
IMUXImmunic
MDWDMediwound
HROWHarrow Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

3 Months
Joseph ThomeTD Cowen
Success Rate
18/28 ratings generated profit
64%
Average Return
+17.80%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +17.80% per trade.
1 Year
Joseph ThomeTD Cowen
Success Rate
21/28 ratings generated profit
75%
Average Return
+50.35%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +50.35% per trade.
2 Years
Graig SuvannavejhMizuho Securities
Success Rate
35/44 ratings generated profit
80%
Average Return
+54.95%
Copying Graig Suvannavejh's trades and holding each position for 2 Years would result in 79.55% of your transactions generating a profit, with an average return of +54.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
1
2
2
8
Buy
38
35
29
33
25
Hold
2
2
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
41
38
32
37
35
In the current month, AXSM has received 33 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 285.88.
Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$0.62 with a range of -$1.00 to -$0.21. The previous quarter’s EPS was -$0.99. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s earnings estimate for AXSM is -$0.62 with a range of -$1.00 to -$0.21. The previous quarter’s EPS was -$0.99. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $250.22M with a range of $227.87M to $262.20M. The previous quarter’s sales results were $218.38M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s sales forecast for AXSM is $250.22M with a range of $227.87M to $262.20M. The previous quarter’s sales results were $218.38M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 285.88.
    What is AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics Inc has 39.13% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AXSM a Buy, Sell or Hold?
          Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Axsome Therapeutics Inc’s price target?
            The average price target for Axsome Therapeutics Inc is 285.88. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $380.00 ,the lowest forecast is $247.00. The average price target represents 39.13% Increase from the current price of $205.48.
              What do analysts say about Axsome Therapeutics Inc?
              Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of AXSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.